Syndax Pharmaceuticals Stock Falls 15% After Axatilimab Fails IPF Trial
Syndax Pharmaceuticals shares fell sharply in after-hours trading on October 12, 2026, after the biotechnology company reported that its experimental drug axatilimab failed to meet the primary goal of a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). The company said it does not plan to continue developing the drug for this lung disease following the disappointing results.
The setback puts pressure on one part of Syndax's development pipeline, but it does not invalidate the drug's existing use in another condition or automatically undermine the company's other programmes. Axatilimab is already approved in the United States for certain patients with chronic graft-versus-host disease (cGVHD), a serious complication that can occur after a stem-cell or bone-marrow transplant. Syndax said the IPF results do not affect its ongoing studies in other indications.
For investors, the key issue is how much value the company had expected to generate from expanding axatilimab into IPF—and whether its approved products and remaining pipeline can continue to support growth.
Why Did Syndax Stock Fall?
The immediate trigger was the failure of the MAXPIRe Phase 2 trial to meet its primary endpoint: the annualized rate of decline in forced vital capacity, or FVC. FVC measures the amount of air a person can forcibly exhale after taking a deep breath and is commonly used to assess lung function in pulmonary fibrosis studies.
Syndax shares dropped approximately 15% in after-hours trading following the announcement, according to market reports.
Clinical-trial results can have an outsized impact on biotechnology stocks because a drug's commercial potential depends on evidence that it works, its safety profile, regulatory decisions and eventual market adoption. When a study misses its primary endpoint, investors may reduce their estimates of the drug's future revenue and the value of the research investment behind it.
The reaction does not necessarily mean that Syndax's entire business outlook has deteriorated by the same amount. It reflects a reassessment of the prospects for the IPF programme and any expectations previously attached to it.
What Happened in the MAXPIRe Trial?
The MAXPIRe study enrolled 145 patients across 62 clinical sites in 14 countries. Participants were randomly assigned in a 2:1 ratio to receive either axatilimab at 0.3 milligrams per kilogram every two weeks or a placebo over a 26-week treatment period.
The trial did not demonstrate the required benefit on its main measure of lung-function decline. Based on the results, Syndax decided not to pursue further development of axatilimab for IPF.
There was, however, a distinction between the trial's efficacy outcome and its safety findings. Syndax reported that axatilimab was generally well tolerated, with a safety profile comparable to placebo and no new safety signals. The company also reported low rates of treatment discontinuation due to adverse events and no treatment-related fatal adverse events in the study.
A treatment can be well tolerated without being effective enough to meet a trial's objectives. In this case, the safety results did not overcome the failure to demonstrate the required effect on lung-function decline.
Why Idiopathic Pulmonary Fibrosis Is a Challenging Market
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease in which scar tissue builds up in the lungs, making breathing increasingly difficult. The term “idiopathic” means that the underlying cause is unknown.
IPF is a difficult condition to treat because established scarring cannot simply be reversed, and slowing further deterioration is a major treatment objective. Clinical trials therefore need to show a meaningful benefit on measures such as lung-function decline while maintaining an acceptable safety profile.
The disease also represents a potential commercial opportunity for drug developers because treatment options remain limited and patients need therapies that can slow progression. But a large unmet medical need does not guarantee that an experimental drug will succeed.
For Syndax, the MAXPIRe failure means axatilimab will not be advanced for this particular disease under the company's current plans. It also removes the potential for future IPF sales that investors might have associated with a successful development programme, although the financial value of that opportunity was not disclosed.
The result highlights a central risk in biotechnology investing: even a scientifically plausible treatment can fail to produce the clinical evidence needed to support further development.
What the Setback Means for Syndax's Remaining Business
The failed IPF trial does not remove axatilimab from Syndax's commercial portfolio. The drug is marketed as Niktimvo for eligible patients with chronic graft-versus-host disease after at least two previous lines of systemic treatment have failed. Syndax is developing it further in combination with standard treatments for patients with newly diagnosed cGVHD.
That distinction matters because the company's future prospects do not depend on a single experimental use of axatilimab.
Syndax also markets Revuforj (revumenib), an approved treatment for certain patients with acute leukaemia. In the second quarter of 2026, the company reported total revenue of $73 million, up 92% from a year earlier. Revuforj generated $54.7 million in net revenue, while Syndax recorded $18.1 million in collaboration revenue from its share of Niktimvo's commercial contribution.
Syndax reported $575.1 million in cash, cash equivalents and short- and long-term investments as of June 30, 2026. That provides financial resources for ongoing development, although it does not guarantee that the company will reach profitability or that every programme will succeed.
The main challenge now is to demonstrate continued growth from its marketed medicines while advancing other clinical programmes. A failed study can also affect how investors evaluate management's research priorities, the expected return on research spending and the probability of success for drugs still in development.
What Investors Should Watch Next
Several developments could help clarify the longer-term impact of the MAXPIRe result:
Frontline cGVHD trial results: Syndax has said it expects results from a Phase 2 study of axatilimab combined with ruxolitinib in the fourth quarter of 2026. A separate Phase 3 study combining axatilimab with steroids is expected to report results in early 2028. These are company-projected timelines and could change.
Revuforj sales growth: Continued demand for the approved leukaemia medicine will be important in assessing whether Syndax can offset setbacks in its experimental pipeline.
Cash use and operating performance: Investors should monitor research and development spending, commercial expenses, cash reserves and the company's path towards sustainable profitability.
Further clinical evidence: Upcoming results from other programmes will help determine whether Syndax can build value beyond its existing products.
The key is to distinguish the loss of one development opportunity from the health of the entire company. The IPF result is clearly negative for axatilimab's prospects in that disease, but its implications for Syndax's overall valuation will depend on how investors weigh the remaining business and pipeline.
Conclusion
Syndax Pharmaceuticals shares tumbled after axatilimab failed to meet the primary endpoint in the MAXPIRe Phase 2 trial for idiopathic pulmonary fibrosis. The company plans to stop developing the drug for IPF, but its approved use in chronic graft-versus-host disease and its other programmes remain in place.
Investors should focus on upcoming cGVHD trial results, sales of Revuforj and Niktimvo, and the company's cash position to assess whether its broader business can withstand the setback. Follow our blog for more pharmaceutical, business and stock-market updates.
This article is for informational and educational purposes only and should not be considered investment advice.